{"organizations": [], "uuid": "ada7ee21b8031192e298610a5ee04bc6acf05d28", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-jazz-announces-fda-acceptance-of-n/brief-jazz-announces-fda-acceptance-of-nda-for-solriamfetol-for-excessive-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea-idUSASB0C8MC", "country": "US", "domain_rank": 408, "title": "BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-02T15:41:00.000+02:00", "replies_count": 0, "uuid": "ada7ee21b8031192e298610a5ee04bc6acf05d28"}, "author": "", "url": "https://www.reuters.com/article/brief-jazz-announces-fda-acceptance-of-n/brief-jazz-announces-fda-acceptance-of-nda-for-solriamfetol-for-excessive-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea-idUSASB0C8MC", "ord_in_thread": 0, "title": "BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "fda acceptance of nda", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "jazz pharmaceuticals plc", "sentiment": "none"}, {"name": "obstructive sleep apnea reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News March 2, 2018 / 1:44 PM / in 6 minutes BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea Reuters Staff 1 Min Read March 2 (Reuters) - Jazz Pharmaceuticals Plc: * JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA * JAZZ PHARMACEUTICALS PLC - SOLRIAMFETOL ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR AN FDA DECISION IS DECEMBER 20, 2018 ​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-02T15:41:00.000+02:00", "crawled": "2018-03-02T15:54:21.000+02:00", "highlightTitle": ""}